Nkarta reports fourth quarter and full year 2021 financial results and corporate highlights

South san francisco, calif., march 17, 2022 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended december 31, 2021.
NKTX Ratings Summary
NKTX Quant Ranking